Publications by authors named "Olivia Haldenby"
Background: There is controversy surrounding the effectiveness of red blood cell (RBC) transfusion for treating anemia in patients hospitalized for acute coronary syndromes (ACS), particularly as hemoglobin (Hb) levels approach and drop below the range of moderate anemia.
Methods: This population-based cohort study followed all adults hospitalized for ACS who experienced an in-hospital nadir Hb between 6.0 and 8.
Background: Despite many atrial fibrillation (AF) patients being at risk of bleeding, very limited data are available on bleeding rates of different direct oral anticoagulants based on the spectrum of bleeding risk.
Objective: We aimed to compare the risk of major bleeding and thromboembolic events with apixaban vs rivaroxaban for AF patients stratified by bleeding risk.
Methods: We conducted a population-based, retrospective cohort study of all adult patients (66 years or older) with AF in Ontario, Canada, who were treated with apixaban or rivaroxaban between April 1, 2011, and March 31, 2020.
Article Synopsis
- There are currently no direct comparisons of the effectiveness and safety of the two most common oral anticoagulants, apixaban and rivaroxaban, for older patients with atrial fibrillation (AF), creating uncertainty regarding which drug is better.
- This study examined older adults (66 and older) in Ontario, Canada, comparing the incidence of major bleeding and thromboembolic events in patients treated with either apixaban or rivaroxaban from 2011 to 2020.
- The findings revealed that apixaban was associated with a significantly lower risk of major and any bleeding compared to rivaroxaban, while both drugs had similar risks for thromboembolic events.